Inhibitory effect of Antineoplaston AlO and AS2-1 on human hepatocellular carcinoma

Kurume Medical Journal

Volumn 43, Issue 2, 1996, Pages 137-147

  Tsuda, Hideaki ^a   Iemura, Akihiro ^a   Sata, Michio ^a   Uchida, Masafumi ^a   Yamana, Kazunari ^a   Hara, Hiroshi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antineoplaston A10; Apoptosis; AS2 1; Cytostasis; Hepatocellular carcinoma

Indexed keywords

3 PHENYLACETAMIDO 2,6 PIPERIDINEDIONE; ANTINEOPLASTIC AGENT; ANTINEOPLASTON A521; DRUG METABOLITE; PHENYLACETIC ACID; PHENYLACETYLGLUTAMINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; HUMAN; HUMAN CELL; LIVER CARCINOMA;

ANTINEOPLASTIC AGENTS; BENZENEACETAMIDES; CARCINOMA, HEPATOCELLULAR; DRUG COMBINATIONS; GLUTAMINE; HUMANS; LIVER NEOPLASMS; PHENYLACETATES; PIPERIDONES; TUMOR CELLS, CULTURED;

EID: 0030036148     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.43.137     Document Type: Article

References (15)

1. Burzynski SR. Antineoplastons; Biochemical defense against cancer. Physiol Chem Phys 1976; 8:275-279.
2. Burzynski SR, and Hai TT. Antineoplaston A10. Drugs of the Future 1985; 10:103-105.
3. Burzynski SR, Mohabbat MO, and Lee SS. Preclinical studies of Antineoplaston AS2-1 and Antineoplaston AS2-5. Drugs Exp Clin Res 1986 (Suppl); 1:25-28.
4. Eriguchi N, Hara H, Yoshida H, Nishida H, Nakayama T et al. Chemopreventive effect of Antineoplaston A10 on Urethane-induced pulmonary neoplasia in mice. J Jpn Soc Cancer Ther 1988; 23 (7):1560-1565.
5. Hendry LB, Muldoon TG, Burzynski SR, Copland JA, and Lerner AF. Stereochemical modelling studies of the interaction of Antineoplaston AlO with DNA. Drugs Exp Clin Res 1987 (Suppl); 1:77-81.
6. Ikeda K, Kumada H, Saitoh S, Arase Y, and Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma: An analysis by Cox proportional hazard model. Cancer 1991; 68:2150-2154.
7. Liau MC, and Burzynski SR. Altered methylation complex isozymes as selective targets for cancer chemotherapy. Drugs Exp Clin Res 1986 (Suppl); 1:77-86.
8. Muldoon TG, Copland JA, and Hendry LB. Actions of Antineoplaston A10 on the genesis and maintenance of specific subpopulations of rodent mammary tumor cells. Advances in Experimental and Clinical Chemotherapy 1988; 1:15-18.
9. Nakao N, Kamino K, Miura K, Hayashi T, Ohnishi M et al. Recurrent hepatocellular carcinoma after partial hepatectomy: value of treatment with transcatheter arterial chemoembolization. Amer J of Radiology 1991; 156:1177-1179.
10. Nishida H, Yoshida H, Eriguchi N, Hoshino K, Kubota H et al. Inhibitory effect of orally administered Antineoplaston A10 on the growth curve of human breast cancer transplanted to athymic mice. J Jpn Soc Cancer Ther 1991; 26:596-601.
11. Okuda K, Fujimoto I, Hanai I, and Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987; 47:4967-4972.
12. Samid D, Yeh T-J and Shack S. Interferon in combination with antitumorigenic phenylderivatives; potentiation of INF alpha activity in vitro. Br J Haematol 1991; 79 (Suppl) 1:81-83.
13. Samid D, Shack S, and Sherman LT. Phenylacetate: A novel nontoxic inducer of tumor cell differentiation. Cancer Research 1992; 52:1988-1992.
14. Tanaka S, Kitamura T, Nakanishi K, Okada S, Yamazaki H et al. Effectiveness of periodic checkup by ultrasonography for the early diagnosis of hepatocellular carcinoma-Cancer 1990; 66:2210-2214.
15. Unoura M, Kaneko S, Matsushita E, Shimoda A, Takeuchi S et al. High risk groups and screening strategies for early detection of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology. 1993; 40:305-310.